Bay City Capital
Signal active
Investment Firm
Overview
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition and agribusiness sector fund.
Highlights
Founded
1997
Industry
Biotechnology
Employees
11-50
Investment
131
Lead Investment
25
Exits
63
Stages
Early Stage Venture, Late Stage Venture, Private Equity, Seed
Investor Type
Venture Capital
Location
United States, North America
Contact Information
Social
Profile Resume
Bay City Capital, established in 1997 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture, Private Equity, Seed investments across Biotechnology, Health Care, Pharmaceutical, Oncology, Financial Services, Venture Capital, Finance, Consumer, Business Development, Hedge Funds. The organization boasts a portfolio of 131 investments, with an average round size of $36.7M and 63 successful exits. Their recent investments include Sunesis Pharmaceuticals, New Enterprise Associates, Venrock, Alta Partners, Nextech Invest. The highest investment round they participated in was $313.1B. Among their most notable exits are Sunesis Pharmaceuticals and New Enterprise Associates. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Bay City Capital has made 131 investments. Their most recent investment was on May 04, 2021, when Oculis raised $57.0M.
Bay City Capital has made 14 diversity investments. Their most recent diversity investment was on Jun 14, 2017, when Twist Bioscience raised $27.0M.
investments
131
Diversity investments
14
Lead investments
25
Number of exits
63
Investments
131
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Mar 02, 2020 | Xilio Therapeutics | Biotechnology | 100.5M |
| Oct 01, 2020 | Sembiosys Genetics | Biotechnology | null |
| Nov 13, 2020 | Bridge Medicines | Pharmaceutical | 10.0M |
| May 04, 2021 | Oculis | Biotechnology | 57.0M |
Sembiosys GeneticsExits
63
Funding Timeline
Funding rounds
131
Investors
0
Funds
6
Funding Rounds
131
Bay City Capital has raised 131 rounds. Their latest funding was raised on May 04, 2021 from a Series C - Oculis round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Mar 02, 2020 | Series B - Xilio Therapeutics | - | 100.5M | - |
| Oct 01, 2020 | Venture Round - Sembiosys Genetics | - | 0 | - |
| Nov 13, 2020 | Venture Round - Bridge Medicines | - | 10.0M | - |
| May 04, 2021 | Series C - Oculis | - | 57.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.